drugset / Trial / NCT00334958

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958

Phase 3 Completed 356 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).

Timeline

Start
2006-02-13
Primary completion
2009-05-20
Completion
2009-05-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rufinamide Small molecule 1600 mg Oral

Indications